David Goldblatt

Immunobiology Section
University College London, Great Ormond Street Institute of Child Health
Great Ormond Street Hospital NHS Foundation Trust

David Goldblatt is Professor of Vaccinology and Immunology at the Great Ormond Street Institute of Child Health, University College London (UCL) where he also holds the role of Deputy Director for NHS Engagement.

He is a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Foundation Trust where he is also Director of Clinical Research and Development. He obtained his medical degree from the University of Cape Town, South Africa, a PhD in Immunology from the University of London, United Kingdom and is a Fellow of both the Royal College of Paediatrics and Child Health and the Royal College of Physicians. He is an Emeritus National Institute for Health Research (NIHR) Senior Investigator.
He has a long-standing interest in the immune response to vaccines and infectious diseases. He has an active research programme exploring the immune response to bacterial carriage and infection, studying bacterial conjugate vaccines (especially S. Pneumoniae) with a program assessing alternative vaccines schedules.  His interest in functional immunity has led to the development of functional assays for evaluating immunity to bacterial candidate vaccines including Group A and Group B Streptococcus as well as Klebsiella Pneumoniae. He recently established a platform for evaluating humoral immunity to SARS-CoV-2 with focus on developing correlates of protection to accelerate COVID19 vaccine licensure. He is a regular advisor to the World Health Organisation (WHO) on vaccines and is Director of the WHO Reference Laboratory for Pneumococcal Serology based at UCL as well as co-director of the UCL NIHR Mucosal Pathogen Research Unit (2017-2022). He serves on subcommittees of the United Kingdom Department of Health Joint Committee on Vaccines and Immunisation (JCVI) has advised the US FDA, EMA and MHRA on vaccine evaluation and most recently the MHRA on COVID Vaccine licensure via membership of the Commission on Human Medicines COVID-19 Vaccines Benefit Risk Expert Working Group.